A history lesson

When Sports Injury Bulletin (SIB) first began, it was a periodical that came in the post. Despite the challenges of the overseas mail system, SIB enjoyed a robust international audience. The expansion of the internet then enabled SIB to transition to an e-zine format, with each issue distributed in a PDF file via email, making an even broader distribution possible. Today, SIB embraces another evolution and becomes a web-based publication.

As much as things change, much remains the same. Sports Injury Bulletin continues to employ a pool of immensely talented writers and clinicians who bring the latest in sports science to your practice. As always, SIB is subscription based, meaning advertising dollars do not sway or color our reporting or the information we bring to readers. And, you can still print articles for personal use or to share with a colleague at your next journal club.

The changes brought about by the web platform serve to enhance our reader’s experience. The revamped website allows access to SIB anywhere, on any internet-enabled device. In addition to the new content added weekly, the website subscription includes a searchable library of previously published articles. When you want to research a particular injury, SIB is your resource!

As a farewell celebration of sorts, we’ve released a bonus PDF issue taking a ‘best of’ look at our past articles. These articles, also now available to view on the website, highlight some of the cutting-edge research concerning your athletes’ toughest problems. In the lower extremity, medial tibial stress syndrome and proximal hamstring tendinopathy. In the upper extremity, scapula-humeral rhythm, posterior shoulder instability, and grip strength.

We welcome our long-time subscribers to the new web platform and trust within a few clicks it will feel like home. For those new to SIB, come in and have a look around. The internet further expands our reach, yet brings us closer. Thus, we encourage you to share articles you find helpful and connect with us on Facebook and Twitter.  Join the conversation as we continue to bring science to treatment.



Share this
Follow us